the acorda therapeutics ( na ) therapeutics program is a new technology that is a highly effective and effective delivery system for patients with Parkinson s disease. it is a novel and effective drug that is a highly effective and safe drug for patients with Parkinson s disease. we report the first quarter of our research and its success in the last year. we are awaiting the development of a new drug for patients with Parkinson s disease and we are awaiting the development of a preliminary injunction to prevent generics from launching at risk. we will also discuss the current status of this technology and its potential for development.